The Seattle Genetics Medical Writing Fellowship is a one-year, experiential program at Seattle Genetics, Inc. based in Bothell, WA. The purpose of this program is to prepare PharmD fellows for career opportunities in pharmaceutical Medical Writing by providing in-depth biopharmaceutical industry experiences and enhancing clinical knowledge.
The fellow will build medical writing expertise and expand their oncology-based clinical knowledge as an active member of the Medical Writing team. By the end of the fellowship year, the fellow is expected to achieve the following objectives: 1) Gain an understanding of pharmaceutical industry, biotech infrastructure and the role/impact of Medical Writing across the company; 2) Develop data analysis, interpretation, and communication skills; 3) Build proficiencies in the role of medical writer and work cross-functionally to contribute to deliverables that serve healthcare providers, regulatory, patient and business needs; 4) Cultivate industry-appropriate professional skills and promote the role of PharmDs in biotech.
The fellow will gain experience through rotations focusing on regulatory medical writing, publication authoring and development, and clinical trial transparency and disclosure. The fellow will also interact with key cross-functional groups within Seattle Genetics, particularly across the Development organization including Regulatory, Clinical Operations, Biostatistics, Clinical Programming, Clinical Research, Medical Affairs, and Drug Safety, providing support for Seattle Genetics’ marketed products and pipeline programs.
Active participation in Medical Writing-related teams/working groups
Analyze and interpret statistical output and study results for inclusion in clinical and regulatory documents
Participate in cross functional discussion to align on interpretation and presentation of results
Authoring and developing content for varied audiences:
Clinical trial disclosure (Registration, summaries and results postings)
Develop understanding of the regulations and guidance's that affect the medical processes and deliverables
Represent Medical Writing on cross functional project and program teams
Participation in professional skills courses
Travel may include attendance at Medical Writing-focused or industry-specific conferences
A Doctor of Pharmacy (PharmD) degree from an ACPE accredited institution
Relevant Internship or Clerkship experiences
Prior clinical or industry experience is preferred
Prior oncology experience is preferred
Completion of a PGY1 or PGY2 pharmacy residency is a plus
Evidence of appropriate analytical, planning and organizational skills
Basic knowledge of the pharmaceutical industry including Product Development, Manufacturing, Regulatory, Medical Affairs, and Commercial operations
Possess good communication skills, including oral, written and presentation
Self-motivated, energetic, able to work and learn independently
Ability to thrive in a fast-paced, dynamic environment
Seattle Genetics is an equal opportunity employer. All qualified applications will receive consideration for employment without regard to race, age, gender identity, sexual orientation, color, religion, sex, marital status, national origin, protected veteran status, disability status, or any other status protected by federal, state, or local law.
Application deadline is Monday, November 25th, 2019.
Letters of Recommendation are not required with application and are only required upon request.
Internal Number: 2019-631
About Seattle Genetics
Seattle Genetics is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. ADCETRIS® (brentuximab vedotin) uses the company’s industry-leading antibody-drug conjugate (ADC) technology and is approved for the treatment of multiple CD30-expressing lymphomas.
Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing or planned pivotal trials for solid tumors. Enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer use our proprietary ADC technology. Tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for HER2-positive metastatic breast cancer. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.